243 related articles for article (PubMed ID: 33039497)
1. Lymph-directed immunotherapy - Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer.
Feeney OM; Gracia G; Brundel DHS; Trevaskis NL; Cao E; Kaminskas LM; Porter CJH
Adv Drug Deliv Rev; 2020; 160():115-135. PubMed ID: 33039497
[TBL] [Abstract][Full Text] [Related]
2. Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy.
Manspeaker MP; Thomas SN
Adv Drug Deliv Rev; 2020; 160():19-35. PubMed ID: 33058931
[TBL] [Abstract][Full Text] [Related]
3. Enhancing cancer immunotherapy with nanomedicine.
Irvine DJ; Dane EL
Nat Rev Immunol; 2020 May; 20(5):321-334. PubMed ID: 32005979
[TBL] [Abstract][Full Text] [Related]
4. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.
Trevaskis NL; Kaminskas LM; Porter CJ
Nat Rev Drug Discov; 2015 Nov; 14(11):781-803. PubMed ID: 26471369
[TBL] [Abstract][Full Text] [Related]
5. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
Li K; Tian H
J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
[TBL] [Abstract][Full Text] [Related]
6. Application of nanotechnology in circumventing immunotolerance.
Ma Y; Shen Y; Zhu B; Li D; Liu J
Pharmazie; 2020 Oct; 75(10):470-477. PubMed ID: 33305719
[TBL] [Abstract][Full Text] [Related]
7. Treatment duration with immune-based therapies in Cancer: an enigma.
Bantia S; Choradia N
J Immunother Cancer; 2018 Dec; 6(1):143. PubMed ID: 30518409
[TBL] [Abstract][Full Text] [Related]
8. Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery.
Dhas NL; Kudarha RR; Acharya NS; Acharya SR
Crit Rev Ther Drug Carrier Syst; 2018; 35(1):1-64. PubMed ID: 29611470
[TBL] [Abstract][Full Text] [Related]
9. Oral SMEDDS promotes lymphatic transport and mesenteric lymph nodes target of chlorogenic acid for effective T-cell antitumor immunity.
Ye J; Gao Y; Ji M; Yang Y; Wang Z; Wang B; Jin J; Li L; Wang H; Xu X; Liao H; Lian C; Xu Y; Li R; Sun T; Gao L; Li Y; Chen X; Liu Y
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272308
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
11. Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles.
Rodallec A; Sicard G; Fanciullino R; Benzekry S; Lacarelle B; Milano G; Ciccolini J
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1139-1147. PubMed ID: 30354685
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics.
Buss CG; Bhatia SN
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13428-13436. PubMed ID: 32493746
[TBL] [Abstract][Full Text] [Related]
13. Intratumoural administration and tumour tissue targeting of cancer immunotherapies.
Melero I; Castanon E; Alvarez M; Champiat S; Marabelle A
Nat Rev Clin Oncol; 2021 Sep; 18(9):558-576. PubMed ID: 34006998
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
15. A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers.
Akkın S; Varan G; Bilensoy E
Molecules; 2021 Jun; 26(11):. PubMed ID: 34205019
[TBL] [Abstract][Full Text] [Related]
16. Cell and tissue engineering in lymph nodes for cancer immunotherapy.
Najibi AJ; Mooney DJ
Adv Drug Deliv Rev; 2020; 161-162():42-62. PubMed ID: 32750376
[TBL] [Abstract][Full Text] [Related]
17. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy: broadening the scope of targetable tumours.
van den Bulk J; Verdegaal EM; de Miranda NF
Open Biol; 2018 Jun; 8(6):. PubMed ID: 29875199
[TBL] [Abstract][Full Text] [Related]
19. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
[TBL] [Abstract][Full Text] [Related]
20. Lymphatic targeting by albumin-hitchhiking: Applications and optimisation.
Abdallah M; Müllertz OO; Styles IK; Mörsdorf A; Quinn JF; Whittaker MR; Trevaskis NL
J Control Release; 2020 Nov; 327():117-128. PubMed ID: 32771478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
